Skip Navigation


JAC Advance Access originally published online on January 14, 2003
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
51/2/219    most recent
dkg109v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (5)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by McColl, D. J.
Right arrow Articles by Miller, M. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McColl, D. J.
Right arrow Articles by Miller, M. D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Journal of Antimicrobial Chemotherapy (2003) 51, 219-223
© 2003 The British Society for Antimicrobial Chemotherapy

Leading Article

The use of tenofovir disoproxil fumarate for the treatment of nucleoside-resistant HIV-1

Damian J. McColl and Michael D. Miller*

Gilead Sciences, 333 Lakeside Drive, Foster City, CA 94404, USA

Keywords: HIV, antiretrovirals, tenofovir, resistance

The first 150 words of the full text of this article appear below.


   Resistance background
 
Nucleoside reverse transcriptase inhibitors (NRTIs) were the first drugs introduced for the treatment of human immunodeficiency virus-1 (HIV-1) infection. Six NRTIs have been approved for use: zidovudine, stavudine, lamivudine, didanosine, abacavir and zalcitabine. HIV-1 reverse transcriptase (RT) copies the viral RNA genome into the double-stranded DNA required for integration; NRTIs are incorporated into the growing DNA chain and act as chain terminators of this process. Current antiretroviral therapy (ART) for HIV combines one or more NRTIs with a protease inhibitor (PI) and/or a non-nucleoside reverse transcriptase inhibitor (NNRTI), and can achieve high-level suppression of HIV-1 RNA in most HIV-1-infected patients. This has resulted in a dramatic decrease in AIDS mortality.1 Despite successful ART, HIV-1 resistance to NRTIs (as well as to PIs and NNRTIs) can emerge during therapy and result in treatment failure.2 The reasons for this are complex, but fundamentally the RT enzyme of HIV-1 cannot proof-read errors in . . . [Full Text of this Article]


   Clinical virology analyses of tenofovir disoproxil fumarate: study 902
 

   Study 907
 

   Conclusions and commentary
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
K. L. White, J. M. Chen, N. A. Margot, T. Wrin, C. J. Petropoulos, L. K. Naeger, S. Swaminathan, and M. D. Miller
Molecular Mechanisms of Tenofovir Resistance Conferred by Human Immunodeficiency Virus Type 1 Reverse Transcriptase Containing a Diserine Insertion after Residue 69 and Multiple Thymidine Analog-Associated Mutations
Antimicrob. Agents Chemother., March 1, 2004; 48(3): 992 - 1003.
[Abstract] [Full Text] [PDF]